Dec 09, 2024 12:02pm EST Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
Dec 02, 2024 8:05am EST Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Nov 07, 2024 4:01pm EST Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 05, 2024 9:05am EST Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
Oct 31, 2024 8:05am EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
Oct 24, 2024 4:35pm EDT Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
Sep 05, 2024 7:30am EDT Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
Sep 03, 2024 8:00am EDT Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
